The transdermal route of administration allows for local treatment
September 9, 2015 (Miami, FL) – Gensco Pharma launches ColciGel™, a new transdermal medication indicated for the treatment and prophylaxis of acute gout flares in adults.
Gout – an extremely painful form of inflammatory arthritis affects more than 8.3 million Americans today, mostly men. The disease occurs due to an excess of the bodily waste uric acid. The acid is deposited as needle-like crystals in the joints or in soft tissue. These crystals cause redness, swelling, stiffness and intense pain in the joints which in turn can create gout flares.
“Unfortunately gout attacks often occur without warning. This sudden attack is referred to as a “flare” and will normally subside within 3-10 days. During that timeframe, people are often shocked at how excruciating and debilitating the pain becomes “said Marc A. Brenner, DPM, FASPD, Fellow and Past President of the American Society of Podiatric Dermatology and Gensco Pharma Medical Advisory Board Member. “The secret to the treatment of an acute gout attack is to be prepared and treat the flare early.”
A new transdermal gel has been developed to treat the symptoms of gout attacks and is now available by prescription only. “Transdermal ColciGel™ has demonstrated to penetrate the dermal layer at the local site of application and has no clinically relevant systemic presence” says Robert L. Wilbur, Pharm.D., CPh, Director of Research and Development for Gensco Pharma. “Experimental results indicate a decrease in pain associated with gout flares within a few hours. ColciGel™ offers gout sufferers, and physicians that treat these patients, an important new medication option to stay ahead of the horrible pain of the flare before it strikes.”
FK, a native New Yorker and active man in his forties has experienced eight gout flares this year. Each time he has a flare; it appears on his left great toe causing debilitating pain without warning. The oral medication he takes to control his gout no longer prevents the flares and causes gastrointestinal havoc. Through his physician, FK was prescribed ColciGel™ and within a “short period of time, the pain and inflammation started going away without any stomach issues.”
Carlos Alfaras, CEO of Gensco Pharma states, “Our corporate focus is to utilize our resources on innovative research, the development of unique drug delivery systems and manufacturing quality medications helping prescribers, healthcare providers and patients improve health.” If you are suffering from gout, learn more about gout by speaking with your doctor or visiting www.gouteducation.org. For more information on ColciGel™ “patent pending”, visit www.colcigel.com
About Gensco Pharma
Gensco Pharma is a specialty pharmaceutical company focusing on research, development and marketing of transdermal prescription products. As an innovator of pharmaceutical products and the development of patented drug delivery systems, Gensco is dedicated to the continual pursuit of novel and effective therapies that improve health. Gensco products are distributed by supply partners and specialty pharmacies, including but not limited to, AmerisourceBergen, ANDA, BriovaRx, Cardinal, CareMed, Cigna TeleDrug, CuraScript, HD Smith, Henry Schein, McKesson, Magellan Rx, Moore Medical, OncoSource Rx, ProCare Rx and PSS. To learn more about Gensco products, visit online at www.genscolabs.com.
MEDIA CONTACT: Randi Press | Patricia Beitler
Gensco Pharma O: 855.743.6726 – press@genscolabs.com
